Sumary of PM has dealt with the ‘sorry’ question. It might be harder to put the ATAGI questions to rest:
- A paper by the Kirby Institute’s Raina MacIntyre and other authors published in this month’s issue of the international journal Vaccine reported their “risk-benefit analysis for Australians aged 18–59”, comparing the risk of AZ vaccination with the risk of COVID infection.
- The authors concluded: “In Australia, the potential risks of the AZD1222 vaccine in younger adults, who are at low risk of dying from COVID-19, may outweigh the benefits”.
- The article also said: “The latest policy decision to avoid use of this vaccine in adults <
- 60 years in Australia is entirely consistent with past vaccine risk–benefit policy decisions when rare but serious adverse events were identified”.
- That was the same day ATAGI advised against AZ for under 50s, with the government announcing this at a hastily-called night news conference.
- Certainly we know ATAGI’s advice (and the debate it prompted) contributed to vaccine hesitancy including among those for whom AZ is most appropriate – older people – and this is very unfortunate.
- LoadingAt his Thursday news conference, Morrison tried to re-spin his pressure on ATAGI.
- In the Australian Financial Review two economists, Ashley Craig and Matthew Lilley, have criticised ATAGI for not building into its recommendations social benefits versus risks.